The price of Cybin Inc. (AMEX:CYBN) shares last traded on Wall Street fell -2.04% to $0.48.
Based on available information, 6 analysts follow Cybin Inc. (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $1.13, we find $3.75. Given the previous closing price of $0.49, this indicates a potential upside of 665.31 percent. CYBN stock price is now 57.44% away from the 50-day moving average and 19.14% away from the 200-day moving average. The market capitalization of the company currently stands at $109.82M.
Among analysts, 0 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $4.48 as their price target over the next twelve months.
A total of 22.29% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc. shares was purchased by SIMPLIFY ASSET MANAGEMENT INC. during the first quarter worth $240,000. BARCLAYS PLC invested $29,000 in shares of CYBN during the first quarter. In the first quarter, WALLED LAKE PLANNING & WEALTH MANAGEMENT, LLC acquired a new stake in Cybin Inc. valued at approximately $28,000. EVOKE WEALTH, LLC acquired a new stake in CYBN for approximately $12,000. REGENT PEAK WEALTH ADVISORS LLC purchased a new stake in CYBN valued at around $11,000 in the second quarter. In total, there are 75 active investors with 7.86% ownership of the company’s stock.
During the past 12 months, Cybin Inc. has had a low of $0.21 and a high of $1.14. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.10, and a quick ratio of 4.10. The fifty day moving average price for CYBN is $0.3074 and a two-hundred day moving average price translates $0.4022 for the stock.
The latest earnings results from Cybin Inc. (AMEX: CYBN) was released for Mar, 2023.
Cybin Inc.(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
